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ABSTRACT
Dr1 (also known as NC2b) was identified as a
repressor of RNA polymerase (pol) II transcription.
It was subsequently shown to inhibit pol III tran-
scription when expressed at high levels in vitro or
in yeast cells. However, endogenous Dr1 was not
detected at pol III-transcribed genes in growing
yeast. In contrast, we demonstrate that endogenous
Dr1 is present at pol III templates in human cells, as
is its dimerization partner DRAP1 (also called NC2a).
Expression of tRNA by pol III is selectively enhanced
by RNAi-mediated depletion of endogenous human
Dr1, but we found no evidence that DRAP1 influ-
ences pol III output in vivo. A stable association
was detected between endogenous Dr1 and the
pol III-specific transcription factor Brf1. This inter-
action may recruit Dr1 to pol III templates in vivo,
as crosslinking to these sites increases following
Brf1 induction. On the basis of these data, we
conclude that the physiological functions of human
Dr1 include regulation of pol III transcription.
INTRODUCTION
Dr1 (down-regulator of transcription 1, also known as
NC2b—negative cofactor 2b) was ﬁrst identiﬁed in
HeLa nuclear extracts as an activity that binds TBP
and represses pol II transcription (1,2). Later, it was
recognized that Dr1 dimerizes with the cofactor DRAP1
(Dr1-associated protein 1, also known as NC2a) (3,4).
Human Dr1/DRAP1 can repress pol II transcription
in vitro and in vivo from a range of promoters (1–5). Dr1
and DRAP1 are also found in Saccharomyces cerevisiae,
where they are required for viability and seem to function
in a similar manner to the mammalian proteins (4,6–9).
Indeed, the human Dr1 and DRAP1 genes can substitute
for their yeast equivalents (10). Dr1 can exclude TFIIA
and TFIIB from DNA-bound TBP, suggesting a model
in which it binds TBP at the promoter and disrupts for-
mation of a functional pre-initiation complex (1–4,11).
In support of this, a crystal structure revealed the Dr1/
DRAP1 heterodimer as a molecular clamp gripping the
upper and lower surfaces of the TBP/DNA complex and
thereby blocking binding by TFIIB and TFIIA (12). The
heterodimer can also mobilize TBP along DNA (13) and
interact with the largest subunit of elongating pol II (14).
Despite targeting the general transcription machinery,
only a subset of mRNAs responds to Dr1/DRAP1
in vivo. For example, only 17% of pol II-transcribed genes
show changes in expression when DRAP1 is inactivated in
yeast (15,16). Furthermore, many mRNAs are induced by
Dr1/DRAP1, in contrast to original expectations (15–20).
The fact that TBP is required for transcription by pols I
and III raised the possibility that these systems might
respond to Dr1/DRAP1. Indeed, puriﬁed or recombinant
human Dr1 was found to repress transcription of VA and
tRNA genes in vitro by pol III, although transcription
by pol I from an rRNA gene promoter did not respond
(21). The same pattern was observed when Dr1 was
overproduced in S. cerevisiae, with tRNA expression
by pol III repressed, but rRNA expression by pol I
unchanged (7). A mechanistic explanation for pol III
control was suggested by binding assays with recombinant
proteins, which showed that excess Dr1 can disrupt the
interaction of TBP with Brf1, a polypeptide that recruits
pol III to its templates (21). This is consistent with Brf1
bearing strong homology to TFIIB in its TBP-binding
domain (22). However, the evidence for Dr1 as a regulator
of pol III transcription was obtained when it was present
at elevated levels (7,21). In contrast, ChIP experi-
ments revealed minimal crosslinking of endogenous Dr1
or DRAP1 to tRNA genes in growing wild-type yeast
(15,20), raising doubts concerning the physiological rele-
vance of the overexpression data. Here, we have addressed
this issue by RNAi and ChIP approaches in human cells.
We show that endogenous Dr1 and DRAP1 associate with
pol III-transcribed genes when present at natural levels in
growing HeLa cells and that tRNA synthesis is suppressed
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by Dr1 in this situation. Our data provide clear evidence
that the physiological functions of human Dr1 include
tRNA gene regulation.
MATERIALS AND METHODS
Cell lines and culture
HeLa and HEK293T cells were cultured at 37C and 5%
CO2 in DMEM supplemented with 10% FCS, 2mM
L-glutamine, penicillin (100U/ml) and streptomycin
(100U/ml). Brf1-inducible Chinese hamster ovary
(CHO) Tet-Oﬀ cells (23) were cultured in DMEM supple-
mented with 10% doxycycline-free FCS (Clontech), 2mM
L-glutamine, 100U/ml penicillin, 100U/ml streptomycin,
100 mg/ml G418 sulphate and 2 mg/ml doxycycline. For
Brf1 induction, cells were washed twice with PBS and
cultured for 48 h without doxycycline. HeLa cells were
subjected to heat shock by incubating at 45C for
30min. Cells were then either harvested immediately or
left to recover at 37C for 2, 4 or 8 h before harvesting.
Control cells were not subjected to heat shock.
RNAi
HeLa cells were transfected with a shRNA pSUPER
vector, encoding an insert with the sequence 50-GAAGA
AAGGCCAGTTCTCG-30, targeting the mRNA of the
second exon of the Dr1 gene or empty pSUPER vector
(24), or with siRNA targeting the ﬁrst (50-GACUCUUCC
UAAUGUCCGG-30, Ambion) or third (50-GCCCUAUA
UGAAUUAACUG-30, Ambion) exons of human Dr1.
For the DRAP1 RNAi experiments, HEK293T cells
were transfected with siRNA (Ambion) targeting the
second exon (50-CGGACGAAGAGAUUGGGAA-30),
third exon (50-CUAGAGUCGCUGUUGAAGA-30) or
ﬁfth exon (50-CGGUGGAUGGGAACGAAA-30) of
human DRAP1. A validated, non-targeting siRNA
(AM4390844, Ambion) was used as control. Transfections
were performed using the Nucleofector system (Amaxa
Biosystems) for the shRNA or lipofectamine 2000
(Invitrogen) for the siRNAs, according to the manufac-
turers’ recommendations. Cells were harvested 48 h after
transfection.
RT–PCR
RNA was extracted using the TRI reagent (Sigma)
according to manufacturer’s speciﬁcations. cDNA was
synthesized by using 0.2 mg of RNA, random hexanucle-
otide mix (Roche) and Superscript III (Invitrogen),
according to the manufacturers’ recommendations.
RT–PCRs for ARPP P0, Brf1, TFIIB, 5S, U6, 7SL and
tRNA transcripts were performed as previously described
(25–29). RT–PCR for Alu RNA used primers 50-CTTAC
ACGTGTCATCCCAGC-30 and 50-GTAATTCTTTTGT
AGAGACAGACTCAC-30 to give a 113 bp product using
the following cycling parameters: 95C for 3min, 27 cycles
of (95C for 30 s, 54C for 30 s, 72C for 30 s), 72C for
5min. RT–PCR for tRNAMETi used primers 5
0-AGCAGA
GTGGCGCAGC-30 and 50-TTCGATCCATCGACCTC
TG-30 to give a 58 bp product using the following
cycling parameters: 95C for 3min, 24 cycles of (95C
for 30 s, 54C for 30 s, 72C for 30 s), 72C for 5min.
RT–PCR of Dr1 mRNA used primers 50-AGAGCTGG
TGGTGAACTGCT-30 and 50-CCAAGGTTTTCCAAA
CGAGA-30 to give a 228 bp product using the following
cycling parameters: 95C for 3min, 25 cycles of (95C for
30 s, 58C for 30 s, 72C for 30 s), 72C for 5min. RT–
PCR of DRAP1 mRNA used primers 50-GGAACGAAA
AGCAAGGACAA-30 and 50-CGTCCTCTTCATCAGG
TGCT-30 to give 226 bp product using the cycling param-
eters described above. Signal intensities were quantiﬁed
by densitometry, normalized to the respective TFIIB
or ARPP P0 signals and represented in graphs as the
average fold increase or decrease, along with the
standard deviations.
Western blotting
Whole cell extracts were prepared as previously (30).
Western blotting was performed as described previously
(31), using antibody sc-1615 against actin (Santa Cruz
Biotechnology), antiserum 128 against Brf1 (23),
antibodies D9390-01(US Biological) and sc-17272 (Santa
Cruz Biotechnology) against DRAP1. Antisera 1162 and
1163 against Dr1 were raised by immunising rabbits
with synthetic peptides ASSSGNDDDLTIPRA and
SNQAESSQDEEDDDDI, corresponding to human Dr1
residues 2–16 and 161–176, respectively. Bands were
quantiﬁed by densitometry, normalized to the respective
actin signals and represented in graphs as the average fold
increase or decrease, along with the standard deviations.
Co-immunoprecipitation
A total 300 mg of HeLa nuclear extract (Computer Cell
Culture Centre) were incubated for 2 h rotating at 4C
with 5 ml anti-Dr1 (1162) and pre-immune serum in a
ﬁnal volume of 500 ml made up with microextraction
buﬀer (150mM NaCl, 50mM NaF, 20mM HEPES
pH 7.8, 25% glycerol, 1mM DTT, 0.5 mM phenylmethy-
lsulfonyl ﬂuoride, 0.2mM EDTA, 40 mg/ml bestatin, 1 mg/
ml trypsin inhibitor, 0.7 mg/ml pepstatin, 0.5 mg/ml
aprotinin, 0.5 mg/ml leupeptin). Following that, 25 ml of
packed protein G sepharose beads (Sigma) were used
per immunoprecipitation and incubated rotating for 1 h
at 4C. The supernatant was then removed and the
beads washed three times with 1ml of PBS containing
0.05% Igepal (Sigma).
Brf1 was also in vitro transcribed and translated using
the TNT reticulocyte lysate kit (Promega), according to
the manufacturer’s instructions, and radiolabelled using
35S-methionine (Amersham Biosciences). HeLa nuclear
extract and in vitro translated protein were pre-cleared
and then incubated with the antibodies for 2 h rotating
at 4C, before 25 ml of protein A sepharose beads were
added and the incubation continued for another hour.
The beads were washed ﬁve times with TBS and the
bound material was analyzed by SDS–PAGE and
autoradiography.
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Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were per-
formed as previously described (32), with the exception
that a Bioruptor (UCD-200, Diagenode) sonicator was
employed. The samples were sonicated at 4C in two
rounds of 15min each (high power—320 W, 30 s on, 30 s
oﬀ), with the water tank supplemented with crushed ice.
Immunoprecipitations were carried out using antisera
1162 or 1163 or antibody Ab28185 (Abcam) against
Dr1, antibodies TM-301A-55 (Austral Biologicals) and
sc-17272 (Santa Cruz Biotechnology) against DRAP1,
antibody MTBP-6 against TBP (33), antiserum 128
against Brf1 (34), antiserum 1900 against pol III (35).
Pre-immune serum and normal goat (sc-2028), rabbit
(sc-2027) or mouse (sc-2025) IgGs (all from Santa Cruz
Biotechnology) were used as controls.
Immunoprecipitated DNA was analysed by PCR using
primers and ampliﬁcation conditions which have been
previously described (26,32,36–39). For the ampliﬁcation
of Hsp70 DNA, the primers 50-GGAGGTGCGGGAAG
GTTCG-30 and 50-TTCTTGTCGGATGCTGGA-30 were
used to give a 187 bp product using the following cycling
parameters: 95C for 3min, 28 cycles of (95C for 30 s,
58C for 30 s, 72C for 30 s), 72C for 5min. Serial dilu-
tions of input chromatin were used to establish that PCRs
were in the linear range. Signal intensities were quantiﬁed
by densitometry, normalized to input and represented in
graphs as the average fold increase along with the
standard deviations.
For sequential ChIP experiments, 5 107 cells per
primary antibody were harvested and treated for ChIP as
previously described (32). To reduce nonspeciﬁc binding,
the primary antibodies were crosslinked to protein A beads
(Sigma) with 10mg/ml dimethyl pimelimidate 2 HCl
(DMP). Speciﬁcally, 100 ml of protein A beads (50%
slurry) were washed three times with 1% NP40/PBS,
prior to incubating with 5 mg of antibody or control
IgG (Sigma) for 2 h, rotating at 4C. This was followed
by three washes with 1% NP40/PBS and two washes
with 100mM HEPES–NaOH pH 8.5. The beads were
then incubated with 10mg/ml DMP in 100mM HEPES–
NaOH pH 8.5, for 1 h, rotating at room temperature,
before being washed twice with 100mM HEPES–NaOH
pH 8.5 and incubated with 1M glycine pH 7.5, for
30min, rotating at room temperature. Following two
washes with TE (10mM Tris, 1mM EDTA, pH8.0), the
beads were incubated overnight with the sonicated mate-
rial, rotating at 4C. After washes performed as previously
(32), the immunoprecipitated material was eluted with
400ml 1% SDS/TE, which was then 10-fold diluted with
TE and subjected to another round of ChIP with the
addition of 5 mg of secondary antibodies or the 1162
pre-immune serum (25 ml) and overnight incubation at 4C.
RESULTS
Dr1 knock-down increases tRNA expression in
human cells
Addition of a large excess of recombinant Dr1 to HeLa
extracts was shown to inhibit transcription of pol III
templates in vitro (21). We adopted an RNAi approach
to test if endogenous human Dr1 inﬂuences expression
of pol III transcripts in vivo. HeLa cells were transfected
with siRNA targeting the ﬁrst exon of Dr1 or a non-
targeting control siRNA and harvested 48 h later.
Western immunoblotting revealed that Dr1 protein levels
were reduced by about 40% (Figure 1A and B), while
the corresponding mRNA, as revealed by RT–PCR,
was reduced by about 60% compared to the control
(Figure 1C and D). Such treatment resulted in signiﬁcant
upregulation of each tRNA examined. This was the case
for mature tRNAMETi , as well as short-lived primary tran-
scripts that reﬂect ongoing transcription (pre-tRNATyr
and pre-tRNALeu). Alu RNA expression also increased,
but 5S rRNA, U6 snRNA and 7SL RNA levels showed no
signiﬁcant response to the Dr1 siRNA (Figure 1C and D).
Control experiments conﬁrmed that assay conditions
were not saturated and that changes in transcript levels
gave a clear change in signal intensity for each primer set
(Supplementary Figure S1).
To validate these results, Dr1 was also depleted with a
second siRNA and a shRNA (24) targeting exons 3 and 2,
respectively. These gave comparable levels of Dr1 knock-
down to the siRNA against exon 1 and produced identical
eﬀects on pol III transcript expression (Supplementary
Figures S2 and S3). It is therefore unlikely that the
observed responses reﬂect oﬀ-target eﬀects, as they were
obtained by targeting three independent regions of the
Dr1 sequence. It is worth noting that the outcome was
unchanged whether we normalized against ARPP P0,
GAPDH or TFIIB mRNAs. Our data suggest that
endogenous Dr1 is an inhibitor of tRNA expression, but
does not show the more general pol III regulatory
properties that we had expected. Thus, as found for pol
II transcription (19,40), the eﬀects of Dr1 on pol III
output may be gene-selective in vivo.
Dr1 is found at pol III-transcribed genes in
human cells
Although Dr1 and DRAP1 have been shown to be
present at pol II-transcribed genes (15,41,42,43), they
were not found at pol III templates in wild-type
yeast (15,20). Nevertheless, ChIP experiments revealed
the presence of endogenous human Dr1 at pol
III-transcribed genes in HeLa cells (Figure 2A). Not
only was Dr1 detected at tRNA genes, but it was also
detected at 5S rRNA and U6 snRNA genes, expression
of which was unperturbed by siRNAs and shRNA
against Dr1. Binding is speciﬁc, as it is not observed
further upstream of the U6 gene or at a site within the
coding region of the ARPP P0 gene. It was conﬁrmed
with an alternative Dr1 antibody (Figure 2B) and in a
diﬀerent human cell type, the osteosarcoma line U2OS
(data not shown). Furthermore, occupancy seems compa-
rable to that detected at two pol II promoters that were
used as positive controls, as judged by comparison with
the TBP signal. Thus, the Dr1 ChIP signals were 50%
and 70%, respectively, as strong as the TBP ChIP
signals at the Hsp70 and U1 snRNA promoters, and
the Dr1 signals at 5S, tRNA and U6 genes were 50%
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of the TBP signals (Supplementary Figure S4). Because
the eﬃciencies of the antibodies may diﬀer, such a com-
parison of ChIP signals does not reveal what proportion
of TBP molecules are bound by Dr1 at these sites, but it
does suggest that the pol III-transcribed genes examined
are targeted as strongly by Dr1 as the Hsp70 promoter.
We conclude that, in contrast to the situation in yeast
(15,20), endogenous Dr1 can be readily detected at pol
III-transcribed genes in human cells.
Endogenous Dr1 associates with TFIIIB
To be recruited to pol III promoters without TATA
boxes, such as the 5S and tRNA genes examined here,
TBP binds to Brf1, a TFIIB-homologous polypeptide
that is anchored to promoters through the DNA-binding
factor TFIIIC (22). A model was proposed by White et al.
(21) in which Dr1 binding to TBP prevents its interac-
tion with Brf1 and thereby blocks TBP recruitment to
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Figure 1. Dr1 knock-down by RNAi results in upregulation of tRNA expression. HeLa cells were transfected with siRNA targeting the ﬁrst exon of
Dr1 and harvested 48 h later. A validated, non-targeting siRNA was used as control. (A) Western analysis for Dr1 from whole-cell extracts of control
and Dr1 targeted cells. Actin was used as loading control. (B) Quantiﬁcation of Dr1 western blotting signals from three independent experiments. (C)
RT–PCR analysis of RNA expression. The pol II-transcribed ARPP P0 gene was used as control. (D) Quantiﬁcation of the RT–PCR analysis signals
from three independent experiments. 5S, LEU, TYR, MET and U6 refer to 5S rRNA, pre-tRNALeu, pre-tRNATyr, tRNAMETi and U6 snRNA,
respectively.
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TATA-less pol III templates (Figure 3A). This model is
contradicted by the clear ChIP signal that we detect for
Dr1 at tRNA and 5S rRNA genes (Figure 2). We there-
fore examined a second prediction of the model, which
was that Dr1 and Brf1 would not be present in the
same complex (Figure 3A). However, when mixed
with a HeLa cell extract, 35S-radiolabelled Brf1 can
be co-immunoprecipitated with Dr1 (Figure 3B).
Furthermore, a stable association of endogenous
Dr1 and Brf1 from HeLa cells can also be detected
(Figure 3C). To investigate the signiﬁcance of this inter-
action, we used stably-transfected cells in which expres-
sion of Brf1 is controlled by a doxycycline-sensitive
promoter (23). Induction of Brf1 by doxycycline with-
drawal was found to increase crosslinking of TBP and
Dr1, as well as Brf1 itself, to tRNA and 5S rRNA genes
(Figure 3D). Speciﬁcity was established using preimmune
serum and control IgG. Western blotting conﬁrmed that
the increased Dr1 ChIP signal following Brf1 induction is
not due to an increase in its abundance (Figure 3E). These
data suggest that Brf1 can mediate recruitment of Dr1 to
tRNA and 5S rRNA genes in vivo, although they do not
establish if this reﬂects a direct interaction. In support
of Brf1-mediated recruitment, sequential ChIP (re-ChIP)
experiments demonstrated simultaneous promoter associ-
ation by Brf1 and Dr1, as well as by Dr1 and TBP
(Figure 3F). As positive control, we conﬁrmed the
expected gene co-occupancy of pol III with Brf1 and TBP.
Endogenous DRAP1 is present at pol III-transcribed
genes
Since Dr1 is known to associate with DRAP1, we used
ChIP to examine whether the latter can also be detected at
pol III-transcribed genes in human cells. This was found
to be the case, with endogenous DRAP1 crosslinking to 5S
rRNA, tRNA and U6 snRNA genes in vivo (Figure 4A).
The interaction appears speciﬁc, as it was not detected
upstream of a U6 snRNA gene or within the coding
region of the ARPP P0 gene. Moreover, it was conﬁrmed
using an alternative antibody against DRAP1 (Figure 4B).
We conclude that endogenous DRAP1 is also present at
pol III-transcribed genes in HeLa cells. A ChIP-on-chip
study carried out previously with human B cells did not
report DRAP1 at pol III-transcribed genes, but this can
be readily explained by the fact that the study focused
speciﬁcally on pol II promoter regions (44).
RNAi was used to assess the inﬂuence of DRAP1
on pol III transcription. However, DRAP1 depletion
(Figure 5A and B) had minimal eﬀects on expression of
pol III products, including the pre-tRNAs that responded
clearly to knockdown of Dr1 (Figure 5C and D). The lack
of response was not because assay conditions were
saturated, since control experiments conﬁrmed that
changes in transcript levels gave a clear change in signal
intensity for each primer set (Supplementary Figure S5).
As a positive control, we examined expression of Bcl2
mRNA and conﬁrmed that this responded to DRAP1
depletion in our assays, as previously reported (19).
Three diﬀerent siRNAs targeting three diﬀerent exons of
DRAP1 were analysed, but although DRAP1 protein
levels were reduced by about 75%, only marginal
changes in pre-tRNA and other pol III transcript levels
were obtained, that were not consistent and did not reach
statistical signiﬁcance (Figure 5 and Supplementary
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Figures S6 and S7). Furthermore, a pool of three addi-
tional siRNAs and a shRNA targeting diﬀerent regions of
DRAP1 were also tested, resulting in similar outcomes
(data not shown). After utilising seven diﬀerent siRNA
and shRNA in both HeLa and HEK293T cells, we
conclude that, at least under the conditions used,
DRAP1 depletion has minimal eﬀect on the expression
of pol III transcripts. This is reminiscent of the pol
II-dependent Egr1 promoter, which responds to depletion
of Dr1, but not of DRAP1 (19).
In addition to examining the eﬀect of DRAP1 deple-
tion, we also considered whether elevated DRAP1 levels
might inﬂuence pol III output in vivo. We found that heat
shock provokes a 5-fold increase in DRAP1 protein with
minimal change in Dr1 levels (Figure 6A and B). This
response appears to be post-transcriptional, as DRAP1
mRNA expression is almost unchanged (Figure 6C
and D). Heat shock therefore provides an opportunity
to examine whether a robust, physiological increase
in DRAP1 levels is accompanied by inhibition of pol III
activity. This was not the case. No decrease was detected
in any of the pol III transcripts examined; indeed, expres-
sion of pre-tRNATyr increased 2-fold after heat shock,
whilst 5S rRNA and pre-tRNALeu showed slight and tran-
sient induction (Figure 6C and E). Our data therefore
provide no evidence that DRAP1 is a repressor of pol
III transcription under the conditions we have studied.
Such a role under other circumstances can clearly not be
excluded.
DISCUSSION
Recombinant human Dr1 was shown previously to inhibit
tRNA gene transcription in vitro (21). The assays,
however, required a large excess of Dr1 protein and there-
fore left open the question of physiological relevance.
Indeed, Dr1 was found to suppress tRNA expression
when produced at elevated levels in yeast (7), even
though endogenous Dr1 is not detected at tRNA genes
when wild-type yeast are grown under standard conditions
(20). Nevertheless, our ChIP assays reveal that human
tRNA genes are occupied by endogenous Dr1 in HeLa
cells, without the need for overexpression. Association is
speciﬁc and was conﬁrmed using alternative antibodies
and in a diﬀerent human cell type. Quantitation of
binding by qPCR conﬁrms that it is highly signiﬁcant
(P< 0.0001; Supplementary Figure S8). Furthermore,
RNAi reveals that transcription of these tRNA genes is
suppressed 2-fold by physiological levels of Dr1. This
response is unlikely to reﬂect oﬀ-target eﬀects, as it was
reproduced using shRNA and siRNAs directed against
three diﬀerent regions of the Dr1 sequence. We conclude
that the functions of human Dr1 include the suppression
of tRNA expression.
As all pol III-transcribed genes are thought to utilize
TBP, we had expected them all to respond to Dr1. We
were therefore surprised that expression of 5S rRNA,
U6 snRNA and 7SL RNA was unchanged by Dr1
RNAi. The corresponding genes clearly associate with
Dr1, as revealed by ChIP. It may be relevant that 5S,
U6 and 7SL genes all have distinct promoter organization
and more complex transcription factor requirements than
the simpler tRNA and Alu genes (22), which might inﬂu-
ence their responsiveness in some way. Promoter sequence
has been shown to inﬂuence responsiveness of pol II pro-
moters to Dr1/DRAP1 (18,19,40). Perhaps 5S, U6 and
7SL genes would respond to more complete depletion of
Dr1 than we have been able to achieve. However, more
extreme depletion is likely to increase secondary eﬀects
that would be diﬃcult to interpret with conﬁdence.
It is also possible that transcriptional changes in fact
occur, but are not reﬂected in the steady-state transcript
levels. Because 5S, U6 and 7SL RNAs are relatively
abundant and stable, their abundance is probably much
less responsive to altered rates of transcription than
short-lived transcripts, such as pre-tRNAs.
We cannot exclude the possibility that the eﬀect of Dr1
on tRNA levels in vivo is mediated indirectly through its
ability to regulate pol II transcription. Clearly, pol III
transcription factors depend on pol II for their expression.
However, the partial depletion of Dr1 in our experiments
is not causing global changes to mRNA expression. We
found no signiﬁcant alteration to the levels of mRNAs
encoding TFIIIB and TFIIIC subunits under RNAi con-
ditions that are suﬃcient to induce tRNA (Supplementary
Figure S9). This is consistent with the selectivity of the
response, as altered expression of pol III or its factors
might be expected to aﬀect a broad range of pol III
products (all the transcription machinery known to be
required by tRNA genes is also required by 5S rRNA
genes, for example). Although indirect eﬀects may also
occur, our data provide clear evidence that human Dr1
interacts with TFIIIB and pol III-transcribed genes
in vivo and therefore support its function as a direct reg-
ulator of these targets, consistent with its pol III inhibitory
eﬀects in vitro with a partially-puriﬁed and reconstituted
system (21).
Structural considerations predict strongly that Dr1 will
obstruct binding of Brf1 to TBP. Two separate domains of
Brf1 interact with TBP, one composed of cyclin folds and
the other referred to as ‘homology II’ (45). Mutagenesis,
crosslinking and modelling suggest that the cyclin fold
domain of Brf1 grasps the C-terminal stirrup of TBP in
a manner similar to the cyclin folds of TFIIB, with which
it bears homology (45). Crystallography shows that this
interaction between TFIIB and TBP is blocked by the
penultimate helix of Dr1 (12). The adjacent helix of Dr1
traverses the convex surface of TBP and is likely to cross
the region occupied by Brf1 homology domain II (46).
This is supported by the ability of recombinant Dr1 to dis-
place TBP from a Brf1 fragment containing homology
domain II (21). These observations predict that
Dr1-bound TBP should dissociate from Brf1 and be
released from TATA-less promoters, where TBP is
anchored by Brf1. Our current data, however, show oth-
erwise. Perhaps interactions with the third TFIIIB
subunit, Bdp1, allow Dr1-bound TBP to be retained
at the promoter despite a disrupted interaction with
Brf1 (Figure 7A). Binding to Brf1 itself might also
explain the presence of Dr1 at pol III-transcribed
genes. A putative interaction with Brf1 could occur
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that does not disrupt the interface with TBP or inhibit
expression. Repression might follow the transfer of Dr1
to TBP, perhaps triggered by phosphorylation changes to
Brf1, TBP and/or Dr1 (Figure 7B). Ample precedent exists
for the presence of Dr1 at active pol II promoters
(15,16,19,20,41), even though its documented interaction
with TBP is incompatible with current models of pol II
transcription. Further structural studies will be required
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Figure 6. DRAP1 protein levels are upregulated after heat shock but do not repress the expression of pol III transcripts. HeLa cells were subjected
to heat shock at 45C for 30min, and then either harvested immediately (0 h) or left to recover for 2, 4 or 8 h prior to harvesting. Control cells were
not subjected to heat shock. (A) Western analysis for DRAP1 and Dr1 after heat-shock. Actin was used as loading control. (B) Quantiﬁcation of
DRAP1 and Dr1 western blotting signals from three independent experiments. (C) RT–PCR analysis for DRAP1 mRNA, Dr1 mRNA and pol III
transcripts after heat-shock. ARPP P0 mRNA was used as control. (D) Quantiﬁcation of the RT–PCR signals for DRAP1 and Dr1 mRNAs from
three independent experiments. (E) Quantiﬁcation of the RT–PCR signals for pol III transcripts from three independent experiments. 5S, LEU, TYR
and U6 refer to 5S rRNA, pre-tRNALeu, pre-tRNATyr and U6 snRNA, respectively.
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to elucidate the disposition of Dr1 in active transcription
complexes.
The Dr1/DRAP1 complex (NC2) can mobilize TBP on
DNA, an eﬀect that may have positive or negative
transcriptional eﬀects, depending on context (13). This
activity is not displayed by Dr1 or DRAP1 individually
(13). Endogenous DRAP1 is clearly detected at pol III
templates (P=0.004; Supplementary Figure S8), presum-
ably due to its dimerization with Dr1. However, DRAP1
depletion by RNAi did not reproducibly aﬀect expression
of pol III products. Furthermore, these transcripts were
not repressed when heat shock triggered a 5-fold
increase in DRAP1 protein levels. DRAP1 may therefore
be a passive partner of Dr1 at pol III-transcribed genes,
with no inﬂuence on their expression. This would imply
that TBP mobilization is not required for Dr1 to regulate
pol III transcription. Dr1 is known to be able to function
independently of DRAP1 in vivo (7,41). Nevertheless, a
role for DRAP1 in pol III control has not been excluded
and might become apparent under diﬀerent experimental
or physiological conditions. Precedent is provided in
yeast, where Dr1/DRAP1 represses certain pol II pro-
moters after diauxic shift, but not during exponential
growth (9,41).
In contrast to our ﬁndings in HeLa cells, little or no
crosslinking of endogenous Dr1 or DRAP1 to tRNA
genes has been detected in S. cerevisiae (15,20).
However, Dr1 is capable of repressing tRNA expression
when overexpressed in this yeast (7). A potential explana-
tion is provided by the observations that Mot1 is found at
yeast pol III-transcribed genes and has been shown to
inhibit promoter association by Dr1 (47). Natural levels
of Dr1 might therefore be excluded from these sites by
Mot1, whereas overexpressed Dr1 may compete more
eﬀectively. Indeed, although the ChIP signal for Dr1
and DRAP1 is close to background at a tRNA gene
in wild-type yeast, it increases signiﬁcantly in a mot1
mutant strain (47).
Pol III output is strongly linked with the growth state of
cells (48,49). Indeed, elevated expression of tRNAMeti in
immortalized murine ﬁbroblasts is suﬃcient to stimulate
proliferation and induce oncogenic transformation (23).
Our data show that levels of this tRNA increase in
response to Dr1 depletion. It is therefore conceivable
that pol III control may provide a link between Dr1 and
the proliferative and oncogenic status of mammalian cells.
Dr1 expression was found to be signiﬁcantly compromised
in 74% of the 58 cases examined of neuroblastoma,
usually due to genomic deletion (50). Little or no change
in DRAP1 was detected in any of the samples (50).
Our data suggest that the reduced Dr1 levels in these
early childhood tumours may result in elevated tRNA
expression.
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